Indication

Progressive diffuse large B-cell lymphoma

Progressive diffuse large B-cell lymphoma (DLBCL) describes an aggressive, fast-growing non-Hodgkin lymphoma that exhibits active disease advancement, increasing tumor burden, or the emergence of new malignant lesions during or following therapy. Read more about Progressive diffuse large B-cell lymphoma

147 drugs 98 manufacturers

Advertisement

Drugs that treat it

Common Progressive diffuse large B-cell lymphoma therapies.

Showing 37–45 of 147 drugs

Filter & compare in the drug finder →Opens the drug finder with Progressive diffuse large B-cell lymphoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Progressive diffuse large B-cell lymphoma.

Progressive diffuse large B-cell lymphoma (DLBCL) describes an aggressive, fast-growing non-Hodgkin lymphoma that exhibits active disease advancement, increasing tumor burden, or the emergence of new malignant lesions during or following therapy.

Arising from mature B lymphocytes within the lymphatic system, this clinical state most commonly affects adults and presents as enlarging lymphadenopathy, extranodal organ involvement (such as the gastrointestinal tract, liver, spleen, or bone marrow), and systemic constitutional B symptoms.

Pathophysiologically, it is defined by the proliferation of large, atypical neoplastic B cells that disrupt normal tissue architecture and evade standard therapeutic suppression, reflecting refractory clonal expansion or treatment resistance.

Personalize your experience

Follow Progressive diffuse large B-cell lymphoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it